Evidence map›Paper›PMID 36333179›Full record

Observational studyThe Lancet. Digital health2022

Forced vital capacity trajectories in patients with idiopathic pulmonary fibrosis: a secondary analysis of a multicentre, prospective, observational cohort.

Hernan P Fainberg, Justin M Oldham, Philip L Molyneau, Richard J Allen, Luke M Kraven, William A Fahy, Joanne Porte, Rebecca Braybrooke, Gauri Saini, Morten A Karsdal and 11 more

Erratum issuedOpen access · goldAbstract readObservational StudyMulticenter Study
In one paragraph

Observational study in The Lancet. Digital health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.American journal of respiratory and critical care medicine · 2024
    Trial
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Altered Metabolism in Idiopathic Pulmonary Fibrosis.Journal of cellular physiology · 2025
    Review
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Circulating biomarker analyses in a longitudinal cohort of patients with IPF.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 4 countries.

Hernan P FainbergNational Heart and Lung Institute, Imperial College London, London, UK. Electronic address: h.fainberg@imperial.ac.uk.
Justin M OldhamDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, USA.
Philip L MolyneauNational Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Richard J AllenDepartment of Health Sciences, University of Leicester, Leicester, UK.
Luke M KravenDepartment of Health Sciences, University of Leicester, Leicester, UK.
William A FahyDiscovery Medicine, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.
Joanne PorteNottingham Respiratory Research Unit, NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Rebecca BraybrookeNottingham Respiratory Research Unit, NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Gauri SainiNottingham Respiratory Research Unit, NIHR Biomedical Research Centre, University of Nottingham, Nottingham, UK.
Morten A KarsdalNordic Bioscience, Herlev, Denmark.
Diane J LeemingNordic Bioscience, Herlev, Denmark.
Jannie M B SandNordic Bioscience, Herlev, Denmark.
Isaac TrigueroComputational Optimisation and Learning Lab, School of Computer Science, University of Nottingham, Nottingham, UK; DaSCI Andalusian Institute in Data Science and Computational Intelligence, University of Granada, Granada, Spain.
Eunice OballaDiscovery Medicine, GlaxoSmithKline Medicines Research Centre, Stevenage, UK.
Athol U WellsNational Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Elisabetta RenzoniNational Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Louise V WainDepartment of Health Sciences, University of Leicester, Leicester, UK; National Institute for Health Research, Leicester Respiratory Biomedical Research Centre, Glenfield Hospital, Leicester, UK.
Imre NothPulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA.
Toby M MaherNational Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Iain D StewartNational Heart and Lung Institute, Imperial College London, London, UK.
R Gisli JenkinsNational Heart and Lung Institute, Imperial College London, London, UK; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Imperial College London · GBNordic Bioscience (Denmark) · DKUniversity of Leicester · GBGlaxoSmithKline (United Kingdom) · GBNottingham Biomedical Research Centre · GBGuy's and St Thomas' NHS Foundation Trust · GBHarefield Hospital · GBUniversidad de Granada · ESUniversity of Michigan–Ann Arbor · USUniversity of Nottingham · GBUniversity of Virginia · US

Funding

1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6M
Architectural structure and regulation of TOLLIP in IPFR01HL130796 · NHLBI · UNIVERSITY OF VIRGINIA · PI NOTH, IMRE · 2016 to 2019
$3.1M
1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
Elucidating the Genomic Determinants of Outcomes in Idiopathic Pulmonary FibrosisK23HL138190 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI OLDHAM, JUSTIN M · 2017 to 2021
$914k
Derivation and validation of a clinical-molecular signature to predict fibrotic progression and treatment response in patients with autoimmune interstitial lung diseaseR56HL158935 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI OLDHAM, JUSTIN M · 2021 to 2021
$400k
Interrogation of the inflammasome to identify biomarkers of progressive interstitial lung diseaseR03HL157895 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI OLDHAM, JUSTIN M · 2021 to 2022
$157k
Department of Health CS-2013–13–017Department of Health RP-2017–08-ST2–014HSRD VA CDA 13-017Medical Research Council G0901226NHLBI NIH HHS K23 HL138190NHLBI NIH HHS R01 HL130796NHLBI NIH HHS R03 HL157895NHLBI NIH HHS R56 HL158935NHLBI NIH HHS UG3 HL145266NHLBI NIH HHS UH3 HL145266
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis is a progressive fibrotic lung disease with a variable clinical trajectory. Decline in forced vital capacity (FVC) is the main indicator of progression; however, missingness prevents long-term analysis of patterns in lung function. We aimed to identify distinct clusters of lung function trajectory among patients with idiopathic pulmonary fibrosis using machine learning techniques.

methodsWe did a secondary analysis of longitudinal data on FVC collected from a cohort of patients with idiopathic pulmonary fibrosis from the PROFILE study; a multicentre, prospective, observational cohort study. We evaluated the imputation performance of conventional and machine learning techniques to impute missing data and then analysed the fully imputed dataset by unsupervised clustering using self-organising maps. We compared anthropometric features, genomic associations, serum biomarkers, and clinical outcomes between clusters. We also performed a replication of the analysis on data from a cohort of patients with idiopathic pulmonary fibrosis from an independent dataset, obtained from the Chicago Consortium.

findings415 (71%) of 581 participants recruited into the PROFILE study were eligible for further analysis. An unsupervised machine learning algorithm had the lowest imputation error among tested methods, and self-organising maps identified four distinct clusters (1-4), which was confirmed by sensitivity analysis. Cluster 1 comprised 140 (34%) participants and was associated with a disease trajectory showing a linear decline in FVC over 3 years. Cluster 2 comprised 100 (24%) participants and was associated with a trajectory showing an initial improvement in FVC before subsequently decreasing. Cluster 3 comprised 113 (27%) participants and was associated with a trajectory showing an initial decline in FVC before subsequent stabilisation. Cluster 4 comprised 62 (15%) participants and was associated with a trajectory showing stable lung function. Median survival was shortest in cluster 1 (2·87 years [IQR 2·29-3·40]) and cluster 3 (2·23 years [1·75-3·84]), followed by cluster 2 (4·74 years [3·96-5·73]), and was longest in cluster 4 (5·56 years [5·18-6·62]). Baseline FEV

interpretationUsing a data-driven unsupervised approach, we identified four clusters of lung function trajectory with distinct clinical and biochemical features. Enriching or stratifying longitudinal spirometric data into clusters might optimise evaluation of intervention efficacy during clinical trials and patient management.

fundingNational Institute for Health and Care Research, Medical Research Council, and GlaxoSmithKline.

Indexed as

Idiopathic Pulmonary FibrosisBiomarkersCohort StudiesHumansProspective StudiesVital CapacityBiomarkers

Identifiers

PMID36333179
PMCPMC12646456
OpenAlexW4307824500

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.